These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 23833274)

  • 101. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes.
    Perry RJ; Samuel VT; Petersen KF; Shulman GI
    Nature; 2014 Jun; 510(7503):84-91. PubMed ID: 24899308
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Insulin signaling, resistance, and the metabolic syndrome: insights from mouse models into disease mechanisms.
    Guo S
    J Endocrinol; 2014 Feb; 220(2):T1-T23. PubMed ID: 24281010
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Molecular pathways in non-alcoholic fatty liver disease.
    Berlanga A; Guiu-Jurado E; Porras JA; Auguet T
    Clin Exp Gastroenterol; 2014; 7():221-39. PubMed ID: 25045276
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Adipose tissue in obesity-related inflammation and insulin resistance: cells, cytokines, and chemokines.
    Makki K; Froguel P; Wolowczuk I
    ISRN Inflamm; 2013 Dec; 2013():139239. PubMed ID: 24455420
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Mechanisms of NAFLD development and therapeutic strategies.
    Friedman SL; Neuschwander-Tetri BA; Rinella M; Sanyal AJ
    Nat Med; 2018 Jul; 24(7):908-922. PubMed ID: 29967350
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Lipotoxicity and the gut-liver axis in NASH pathogenesis.
    Marra F; Svegliati-Baroni G
    J Hepatol; 2018 Feb; 68(2):280-295. PubMed ID: 29154964
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Inflammation in Alcoholic and Nonalcoholic Fatty Liver Disease: Friend or Foe?
    Gao B; Tsukamoto H
    Gastroenterology; 2016 Jun; 150(8):1704-9. PubMed ID: 26826669
    [No Abstract]   [Full Text] [Related]  

  • 108. Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD.
    Paik JM; Golabi P; Younossi Y; Mishra A; Younossi ZM
    Hepatology; 2020 Nov; 72(5):1605-1616. PubMed ID: 32043613
    [TBL] [Abstract][Full Text] [Related]  

  • 109. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.
    Chalasani N; Younossi Z; Lavine JE; Charlton M; Cusi K; Rinella M; Harrison SA; Brunt EM; Sanyal AJ
    Hepatology; 2018 Jan; 67(1):328-357. PubMed ID: 28714183
    [No Abstract]   [Full Text] [Related]  

  • 110. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
    Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
    Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
    [TBL] [Abstract][Full Text] [Related]  

  • 111. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.
    ; ;
    J Hepatol; 2016 Jun; 64(6):1388-402. PubMed ID: 27062661
    [No Abstract]   [Full Text] [Related]  

  • 112. Heme oxygenase 1 alleviates nonalcoholic steatohepatitis by suppressing hepatic ferroptosis.
    Yuan X; Li L; Zhang Y; Ai R; Li D; Dou Y; Hou M; Zhao D; Zhao S; Nan Y
    Lipids Health Dis; 2023 Jul; 22(1):99. PubMed ID: 37422643
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Ferroptosis and Liver Fibrosis.
    Pan Q; Luo Y; Xia Q; He K
    Int J Med Sci; 2021; 18(15):3361-3366. PubMed ID: 34522161
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement.
    Eslam M; Alkhouri N; Vajro P; Baumann U; Weiss R; Socha P; Marcus C; Lee WS; Kelly D; Porta G; El-Guindi MA; Alisi A; Mann JP; Mouane N; Baur LA; Dhawan A; George J
    Lancet Gastroenterol Hepatol; 2021 Oct; 6(10):864-873. PubMed ID: 34364544
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Hypertension in NAFLD: An uncontrolled burden.
    Kasper P; Martin A; Lang S; Demir M; Steffen HM
    J Hepatol; 2021 May; 74(5):1258-1260. PubMed ID: 33485968
    [No Abstract]   [Full Text] [Related]  

  • 116. NAFLD as a continuum: from obesity to metabolic syndrome and diabetes.
    Godoy-Matos AF; Silva Júnior WS; Valerio CM
    Diabetol Metab Syndr; 2020; 12():60. PubMed ID: 32684985
    [TBL] [Abstract][Full Text] [Related]  

  • 117. From NAFLD to MAFLD: when pathophysiology succeeds.
    Tilg H; Effenberger M
    Nat Rev Gastroenterol Hepatol; 2020 Jul; 17(7):387-388. PubMed ID: 32461575
    [No Abstract]   [Full Text] [Related]  

  • 118. GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH).
    Alkhouri N; Lawitz E; Noureddin M; DeFronzo R; Shulman GI
    Expert Opin Investig Drugs; 2020 Feb; 29(2):135-141. PubMed ID: 31519114
    [No Abstract]   [Full Text] [Related]  

  • 119. SREBPs in Lipid Metabolism, Insulin Signaling, and Beyond.
    DeBose-Boyd RA; Ye J
    Trends Biochem Sci; 2018 May; 43(5):358-368. PubMed ID: 29500098
    [TBL] [Abstract][Full Text] [Related]  

  • 120. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes.
    Sberna AL; Bouillet B; Rouland A; Brindisi MC; Nguyen A; Mouillot T; Duvillard L; Denimal D; Loffroy R; Vergès B; Hillon P; Petit JM
    Diabet Med; 2018 Mar; 35(3):368-375. PubMed ID: 29247558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.